(RTTNews) – Swiss biopharmaceutical company Actelion Ltd (ALIOF.PK: News ) on Monday said an exploratory phase II study with macitentan in patients with idiopathic pulmonary fibrosis or IPF did not meet its primary endpoint of forced vital capacity. The company added that the efficacy data is not supportive to initiate a Phase III study.
However, the MUSIC (Macitentan USe in an Idiopathic pulmonary fibrosis Clinical) study showed a promising long-term safety and tolerability profile of the drug.
The double-blind, randomized, placebo controlled, multicenter study evaluated the efficacy and safety of the 10 milligram dose of macitentan or placebo in 178 patients with IPF.
Read the entire article at:
http://www.rttnews.com/Content/BiotechStory.aspx?Id=1701621&Category=ClinicalTrial
or go to www.ipftoday.com for more news.
